drugset / Trial / NCT04004117
Effect of Sublingual Fentanyl on Breathlessness in COPD
Phase 2/3
Terminated
40 enrolled
McGill University Health Centre/Research Institute of the McGill University Health Centre
Canadian Institutes of Health Research (CIHR) · collabRoyal University Hospital, Saskatoon · collab
RandomizedCrossoverQuadruple-blindTreatment
Summary
There is actually no physiologic or clinical data in the literature to clearly define the potential benefits and side effects of sublingual fentanyl in patients with COPD. Therefore, the purpose of this study is to test the hypothesis that sublingual fentanyl will improve exercise capacity and dyspnea control in severe COPD patients experiencing persistent breathlessness despite optimal management.
Timeline
- Start
- 2019-07-01
- Primary completion
- 2019-12-31
- Completion
- 2026-02-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fentanyl | Other / unclassified | 12.5 ug | Other |